Skip to main content
    I

    Intelligent Bio Solutions Inc. (INBS)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.52
    -0.24 (-13.64%)

    Market Cap: $5.84M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Intelligent Bio Solutions Inc. (INBS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Intelligent Bio Solutions reported revenue of $4.22M for the fiscal year ended Jun 30, 2026, up 38.1% from the year before. That year, net income was -$12.47M with a net margin of -295.8%, operating cash flow was -$11.93M and free cash flow was -$12.05M. The quarter ended Sep 30, 2026 had revenue of $1.39M and net income of -$2.67M.

    Revenue and Margins

    Over the 6 years to Jun 2026, revenue grew from $188.74K, a compound annual rate of 67.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Jun 2026$4.22M+38.1%48.6%-299.1%-295.8%
    Jun 2025$3.05M-1.9%40.8%-349.8%-347.4%
    Jun 2024$3.11M+147.6%45.8%-330.5%-327.5%
    Jun 2023$1.26MN/A26.0%-1002.1%-848.5%
    Jun 2022$0-100.0%N/AN/AN/A
    Jun 2021$1.98M+949.3%100.0%-281.4%-356.5%
    Jun 2020$188.74KN/A100.0%-1513.7%-1691.7%
    Jun 2019$0N/AN/AN/AN/A
    Jun 2018N/AN/AN/AN/AN/A
    Jun 2017N/AN/AN/AN/AN/A
    Annual, fiscal years ended Jun 2017 to Jun 2026

    Income Statement

    In the fiscal year ended Jun 2026, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Revenue$4.22M$3.05M$3.11M$1.26M$0$1.98M$188.74K$0N/AN/A
    Cost of revenue$2.17M$1.81M$1.69M$930.20K$0$0$0N/AN/AN/A
    Gross profit$2.05M$1.25M$1.43M$326.67K$0$1.98M$188.74KN/AN/AN/A
    Research and development$0$0$0$0$0$0$0$3.18M$2.53M$0
    Operating income-$12.61M-$10.68M-$10.28M-$12.60M-$8.34M-$5.57M-$2.86M-$6.73M-$4.60M-$173.00K
    Net income-$12.47M-$10.60M-$10.19M-$10.66M-$8.33M-$7.06M-$3.19M-$7.34M-$5.02M-$340.00K
    EBITDA-$11.40M-$9.47M-$8.90M-$9.48MN/AN/A-$2.86M-$6.67M-$417.00K-$151.00K
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.39M$1.15M$1.06M$896.77K$1.11M$843.88K$728.87K$607.49K$872.29K$727.82K$823.80K$764.06K
    Gross profit$758.00K$536.58K$535.38K$459.74K$518.29K$335.58K$341.37K$223.11K$346.80K$815.56K$178.49K$199.25K
    Operating income-$2.68M-$4.03M-$2.95M-$2.64M-$3.00M-$3.13M-$2.56M-$2.26M-$2.73M-$2.81M-$2.95M-$1.99M
    Net income-$2.67M-$3.92M-$2.87M-$2.69M-$2.99M-$3.10M-$2.55M-$2.26M-$2.69M-$2.80M-$2.99M-$1.98M
    Last 12 quarters

    Balance Sheet

    As of Jun 2026, cash and equivalents exceeded short-term debt of $0 by $3.99M.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Total assets$11.94M$8.25M$13.78M$10.35M$12.35M$21.86M$2.48M$2.33M$2.50M$667.23K
    Current assets$7.10M$4.14M$8.53M$3.86M$10.87M$18.21M$2.34M$2.33M$2.50M$667.23K
    Cash and equivalents$3.99M$1.02M$6.30M$1.54M$8.24M$12.57M$427.27K$197.94K$418.42K$56.03K
    Total liabilities$6.65M$5.44M$5.60M$6.67M$5.81M$6.85M$7.69M$6.31M$5.56M$6.58M
    Short-term debt$0$197.15K$515.28K$353.21K$0$137.81K$5.13M$5.13M$4.84M$3.53M
    Long-term debtN/AN/AN/A$402.86K$0N/AN/AN/AN/AN/A
    Shareholder equity$5.51M$3.00M$8.33M$3.80M$6.62M$15.06M-$5.19M-$4.62M-$4.38M-$5.91M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$13.62M$11.94M$14.86M$17.65M$10.04M$8.25M$9.58M$8.68M$11.73M$13.78M$17.04M$8.83M
    Total liabilities$6.27M$6.65M$6.11M$6.76M$6.61M$5.44M$4.64M$4.48M$5.78M$5.60M$6.04M$5.67M
    Cash and equivalents$5.93M$3.99M$6.86M$740.37K$1.66M$1.02M$2.81M$2.24M$3.99M$6.30M$9.40M$1.12M
    Shareholder equity$7.58M$5.51M$8.96M$11.09M$3.62M$3.00M$5.11M$4.37M$6.10M$8.33M$11.13M$3.28M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Jun 2026.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Operating cash flow-$11.93M-$9.68M-$9.57M-$7.38M-$3.36M-$11.30M-$498.62K-$5.58M-$5.38M-$243.89K
    Capital expenditures$125.73K$231.84K$221.43K$0$380.22K$3$380.22K$380.22K$0$0
    Free cash flow-$12.05M-$9.91M-$9.79M-$7.38M-$3.74M-$11.30M-$878.84K-$5.96M-$5.38M-$243.89K
    Share repurchasesN/AN/AN/A$518.91K$0$2.00MN/AN/AN/AN/A
    Investing cash flow-$85.57K-$231.84K-$221.43K-$694.14K-$880.22K$0-$14.00K-$14.00KN/AN/A
    Financing cash flow$14.98M$4.60M$14.56M$1.44M$0$23.40M$733.86K$5.32M$5.18M$299.92K
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.75M-$3.18M-$4.33M-$1.57M-$2.85M-$2.21M-$2.76M-$2.32M-$2.39M-$2.94M-$2.45M-$2.87M
    Capital expenditures$0N/A$12.90K$68.23K$70.40K$208.52K$14.38K$8.94K$0$167.31K$2.55K$56.67K
    Free cash flow-$2.75MN/A-$4.34M-$1.64M-$2.92M-$2.42M-$2.77M-$2.33M-$2.39M-$3.11M-$2.45M-$2.93M
    Last 12 quarters

    Frequently Asked Questions About INBS

    What is Intelligent Bio Solutions' annual revenue?

    Intelligent Bio Solutions reported revenue of $4.22M for the fiscal year ended Jun 30, 2026.

    How fast is Intelligent Bio Solutions' revenue growing?

    Revenue was up 38.1% for the fiscal year ended Jun 30, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 49.7%.

    Is Intelligent Bio Solutions profitable?

    No. Intelligent Bio Solutions reported net income of -$12.47M for the fiscal year ended Jun 30, 2026, with a net margin of -295.8%.

    How much free cash flow does INBS generate?

    For the fiscal year ended Jun 30, 2026, operating cash flow of -$11.93M minus capital expenditures of $125.73K produced free cash flow of -$12.05M.

    How much debt does Intelligent Bio Solutions have?

    The balance sheet dated Jun 30, 2026 reported short-term debt of $0 and cash and equivalents of $3.99M.